What is this medication?
Brentuximab Vedotin, Adcetris
Antineoplastic Agent, Monoclonal Antibody
Indicated for treatment of Anaplastic large cell lymphoma, Hodgkin lymphoma, mycosis fungoides, peripheral T-cell lymphoma.
“Alert: US Warning
JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death can occur in patients receiving brentuximab vedotin.”
How does this medication work?
Brentuximab Vedotin, Adcetris is an antibody drug conjugate (ADC) directed at CD30 consisting of 3 components: 1) a CD30-specific chimeric IgG1 antibody cAC10; 2) a microtubule-disrupting agent, monomethyl auristatin E (MMAE); and 3) a protease cleavable dipeptide linker (which covalently conjugates MMAE to cAC10). The conjugate binds to cells which express CD30, and forms a complex which is internalized within the cell and releases MMAE. MMAE binds to the tubules and disrupts the cellular microtubule network, inducing cell cycle arrest (G2/M phase) and apoptosis.
How should I take this medication?
Usual (IV): 1.2 mg/kg to 1.8 mg/kg (maximum dose: 180 mg) every 3 weeks, continue until disease progression or unacceptable toxicities
How to Take:
IV: Infuse over 30 minutes. Do not administer as IV push or bolus; do not mix or infuse with other medications.
What should I watch for while using this medication?
Before using Brentuximab Vedotin, Adcetris, make sure your physician is aware of any allergies or medications you currently take, pre-existing medical conditions and activities you perform. Bone marrow suppression with evidence of neutropenia, thrombocytopenia and anemia have occurred with the use of Brentuximab vedotin. Brentuximab Vedotin, Adcetris can also cause dermatologic toxicity, cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported (some fatal). Acute pancreatitis (some fatal) has also been observed. Other serious and fatal GI complications (including hemorrhage, obstruction, perforation, erosion, ulcer, enterocolitis, neutropenic colitis, and ileus) have also been reported. Serious hepatotoxicity, including fatalities, has occurred; cases were consistent with hepatocellular injury, with elevations of transaminases and/or bilirubin. Pulmonary toxicity (eg, pneumonitis, interstitial lung disease, acute respiratory distress syndrome), some fatal, has been reported in patients receiving brentuximab vedotin. Tumor lysis syndrome (TLS) may occur; risk of TLS is higher in patients with a high tumor burden or with rapid tumor proliferation. Serious infection, including opportunistic infections (eg, pneumonia, bacteremia, sepsis/septic shock) have been reported (some fatal); monitor for signs or symptoms of bacterial, fungal, or viral infections. Peripheral neuropathy is common and is generally cumulative. Neuropathy is usually sensory, although motor neuropathy has also been observed. Brentuximab vedotin should be used with caution in patients with moderate to severe hepatic and/or renal impairment.
What if I miss a dose?
Call your doctor right away if you miss an appointment for your Adcetris injection.
How should I store this medication?
Store vial in the refrigerator at 2-8°C (36-46°F) in the original carton to protect from light, and moisture. Discard any vials after the expiration date.
What are the possible side effects of using this medication?
Peripheral edema, neuropathy, peripheral sensory neuropathy, fatigue (24% to 29%), peripheral motor neuropathy, headache, pruritus, alopecia, maculopapular rash, weight loss, nausea, diarrhea, vomiting, decreased appetite, abdominal pain, constipation, neutropenia, anemia, thrombocytopenia, antibody development, arthralgia, myalgia, asthenia, muscle spasm, upper respiratory tract infection, cough, dyspnea, fever, chills, cellulitis, hyperglycemia, hepatotoxicity, pulmonary toxicity, pneumonia
Note this is not a complete list of side effects, only the most common.
- Choosing a selection results in a full page refresh.
- Press the space key then arrow keys to make a selection.